Evidence map›Paper›PMID 41309494›Full record

ArticleAdvanced science (Weinheim, Baden-Wurttemberg, Germany)2026

scPER: A Rigorous Computational Approach to Determine Cellular Subtypes in Tumors Aligned With Cancer Phenotypes From Total RNA Sequencing.

Bingrui Li, Xiaobo Zhou, Raghu Kalluri

Abstract read
In one paragraph

Article in Advanced science (Weinheim, Baden-Wurttemberg, Germany), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Bingrui LiDepartment of Cancer Biology, University of Texas MD Anderson Cancer Center, Houston, TX, 77054, USA.ORCID https://orcid.org/0000-0002-4807-1452
Xiaobo ZhouCenter for Computational Systems Medicine, School of Biomedical Informatics, The University of Texas Health Science Center at Houston, Houston, TX, 77030, USA.
Raghu KalluriDepartment of Cancer Biology, University of Texas MD Anderson Cancer Center, Houston, TX, 77054, USA.ORCID https://orcid.org/0000-0002-2190-547X

Funding

The RAS and P13K Pathways in Pancreatic AdenocarcinomaP01CA117969 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI DEPINHO, RONALD ANTHONY · 2006 to 2025
$41.7M
Multiscale Resolution and Deep Network Approaches for Deconvolving Different Cell Types in Bulk Tumor using Single-cell Sequencing Data (scDEC)R01CA241930 · NCI · UNIVERSITY OF TEXAS HLTH SCI CTR HOUSTON · PI ZHOU, XIAOBO · 2019 to 2023
$2.7M
Microbial-based platform for assessing organ damage in alcohol use disorders (AUD)R01AA032723 · NIAAA · UNIVERSITY OF TEXAS HLTH SCI CTR HOUSTON · PI Faraz Bishehsari, Xiaobo Zhou · 2025 to 2026
$1.2M
Optimizing mRNA sequences with deep neural networksR01LM014156 · NLM · UNIVERSITY OF TEXAS HLTH SCI CTR HOUSTON · PI Xiaobo Zhou · 2024 to 2026
$1.1M
Developing mRNAdesigner tool package for optimization of mRNA sequenceR01GM153822 · NIGMS · UNIVERSITY OF TEXAS HLTH SCI CTR HOUSTON · PI ZHOU, XIAOBO · 2024 to 2025
$624k
CPRIT RP250043MD Anderson Cancer CenterNational Science Foundation NSF2217515National Science Foundation NSF2326879NCI NIH HHS P01 CA117969NCI NIH HHS R01 CA241930NIAAA NIH HHS R01 AA032723NIGMS NIH HHS R01 GM153822NIH HHS P01CA117969NIH HHS R01AA032723NIH HHS R01CA241930NIH HHS R01GM153822NIH HHS R01LM014156NLM NIH HHS R01 LM014156Sid W. Richardson Foundation
6 · The paper itself

Abstract

Single-cell RNA sequencing (scRNA-seq) is a powerful technique for understanding cellular diversity, but processing large patient cohorts to identify phenotype-associated cell populations remains challenging. Here, scPER (Estimating cell Proportions using single-cell RNA-seq Reference), a rigorous approach combining adversarial autoencoder and extreme gradient boosting to estimate tumor microenvironment cell compositions and identify phenotype-associated subclusters for bulk RNA-seq samples. Integrating scRNA-seq datasets from diverse studies, scPER constructed comprehensive reference panels and disentangled confounders from true signals. scPER achieved superior accuracy in cellular proportion estimation compared to CIBERSORTx, BayesPrism, Scaden, MuSiC, SCDC, DeSide and ReCIDE. It showed high accuracy in predicting metastatic melanoma immunotherapy response and identified a critical T cell subcluster expressing FCRL3 and SLAMF7. In metastatic urothelial cancer, scPER predicted TGFβ-mediated inhibition of CD4 naïve T cells to diminish PD-L1 checkpoint blockade efficacy. scPER enables robust integration of scRNA-seq datasets to estimate cellular proportions across tumors and identify clinically relevant cell populations.

Indexed as

Computational BiologyNeoplasmsSequence Analysis, RNASingle-Cell AnalysisHumansMelanomaPhenotypeRNA-SeqTumor Microenvironmentcancer biologydeconvolutionmachine learningtumor microenvironment

Identifiers

PMID41309494
PMCPMC12884779

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.